



5-3-05

CASE PA/4-30602B

IPW  
AB

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV483664238US

Express Mail Label Number

may 2. 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
DE BRUIJN ET AL.  
APPLICATION NO: 10/620,178  
FILED: JULY 15, 2003  
FOR: NEW ORAL FORMULATION

Art Unit: 1614

Examiner: Delacroix Muirhei, Cybille

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed July 15, 2003. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Edward J. Wilusz, Jr.  
Attorney for Applicants  
Reg. No. 52,370

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7960

Date: April 29, 2005



CASE PA/4-30602B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV483649233US</u> Express Mail Label Number	<u>May 2, 2005</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
DE BRUIJN ET AL.  
APPLICATION NO: 10/620,178  
FILED: JULY 15, 2003  
FOR: NEW ORAL FORMULATION

Art Unit: 1614

Examiner: Delacroix Muirhei, Cybille

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


FEEL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.


Respectfully submitted,



Edward J. Wilusz, Jr.  
Attorney for Applicants  
Reg. No. 52,370

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7960

Date:



(Use several sheets if necessary)

ATTY. DOCKET NO.  
PA/4-30602B  
APPLICATION NO.  
10/620,178  
APPLICANT  
DE BRUIJN ET AL.  
FILING DATE  
JULY 15, 2003Group  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
AM	WO 97/22340	12/19/96	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
AN	JP 9-194374A (English Translation)	11/8/96	Japan			<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.